[Indicators of nonspecific immunity in patients with non-Hodgkin's lymphoma of high grade malignancy in the remission phase of the disease].
Parameters of unspecific immunity (absolute numbers of peripheral blood lymphocytes and their subpopulations, monocytes, blood concentrations of G, A, M immunoglobulins and skin tests with recall-antigens) were evaluated in 25 patients with high grade malignancy non-Hodgkin lymphomas at diagnosis. The frequency, site and gravidity of infections were recorded during the cytostatic treatment with the use of CHOP or CBVPP/ABVD regimens. The same immunological parameters were reevaluated in 9 patients in remission, within 6-52 months following treatment's cessation. Disturbances in at least 2 out of 10 studied parameters were found in all 25 patients at diagnosis. While on treatment, 19 out of 25 patients suffered from various bacterial, viral or fungal infections. The diminished frequency of infections was observed after treatment cessation, in contrast to persisting immunological disturbances. The usefulness of the immunological status monitoring and of immunomodulatory treatment during the remission phase of NHL is postulated.
Urasiński
I
I
Kliniki Hematologii Instytutu Chorób Wewnetrznych PAM w Szczecinie.
Zdziarska
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D001761:Bleomycin / Q000008:administration & dosage; D016516:CD4-CD8 Ratio / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis* / Q000187:drug effects; D007958:Leukocyte Count / Q000187:drug effects; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage
D007136:Immunoglobulins; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate
Wskaźniki odporności nieswoistej u chorych na chłoniaki nieziarnicze o wysokiej złośliwości w remisji choroby.